Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.

Ghina Harika-GermaneauNicolas LangbourSylvie PatriMarcello SolinasArmand ChatardBruno MilletFarshad HashemianMarie-Christine Pérault-PochatNematollah JaafariClaire Lafay-Chebassier

Published in: CNS spectrums (2021)

Our findings do not support the usefulness of BDNF Val66Met genotyping to predict overall response to treatment with SRIs in OCD; they did however suggest a better outcome at 6 months for the aggressive/checking symptom dimension for patients carrying the Met allele.

Keyphrases

obsessive compulsive disorder
tyrosine kinase
end stage renal disease
ejection fraction
deep brain stimulation
newly diagnosed
chronic kidney disease
prognostic factors
patient reported
high throughput
genome wide
dna methylation
genetic diversity